Discontinued — last reported Q4 '25
Coherent Interest Paid decreased by 47.8% to $32.35M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 28.6%, from $45.31M to $32.35M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 62.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.30M | $8.33M | $7.78M | $8.05M | $33.16M | $45.96M | $81.08M | $63.63M | $92.16M | $67.32M | $92.22M | $65.12M | $88.22M | $63.43M | $79.05M | $45.31M | $68.91M | $41.00M | $62.03M | $32.35M |
| QoQ Change | — | -56.9% | -6.6% | +3.5% | +311.7% | +38.6% | +76.4% | -21.5% | +44.8% | -27.0% | +37.0% | -29.4% | +35.5% | -28.1% | +24.6% | -42.7% | +52.1% | -40.5% | +51.3% | -47.8% |
| YoY Change | — | — | — | — | +71.8% | +452.0% | +942.4% | +690.1% | +178.0% | +46.5% | +13.7% | +2.3% | -4.3% | -5.8% | -14.3% | -30.4% | -21.9% | -35.4% | -21.5% | -28.6% |